The Company's focus is on the development of anti-inflammatory treatments for rare diseases with significant unmet needs. Proteo is engaged in the development of pharmaceuticals based on the body's own tools and weapons to fight inflammatory diseases.

News

2017-12-18

Further confirmation of Elafin’s potential to prevent oxygen-induced lung injury in mechanically ventilated newborns




PROTEO BIOTECH AG
Am Kiel-Kanal 44
24106 Kiel
Germany
phone: +49 431 8888462
https://proteo.de/pages/ – printed on 2018-04-21 17:28:50